Ceftazidime(CA2) i s a broad speftrum' antibiotic with activity against most neonatal pathogens including Ps.aeruginosa.It has proved efficacious in the treatment of infected neonates.The pharmacokinetics and safety of CAZ(25 mg/kg twice daily I V or I M were examined in 41 young premature neonates with clinical evidence pf infection. CAZ was assayed in 46 series of blood samples by flPLC.Blood was collected before,during and after therapy for analysis of biochemical and haematological factors.Faeca1 specimens bere examined for Cl .difficile and i t s toxin.Pharmacokinetic
I
arameters were:CMAX=72 6mgII;CMIN=l7 2mg/l;TMAX=1.5 0.3hrs;T1/2=8.6 .2hrs; total body clearance(CL)=0.8 0.07ml/min/kg) .CMAX(IV) CAZ was 7 8mg/l and CMAx(1M) was 56 7 mg/l .Therapeutic serum levels were naintained throughout the dosage interval in a l l babies. CL of CAZ hncreased with increasing postnatal age (p<0.0001) but was lnaffected by birthweight or gestational age. Serum ~rea,electrolytes,urine sp.gr and body temperature had no effect of ;AZ pharmacokinetics.These data were compared with studies of zomparable babies receiving cefuroxime(24) ,cefotaxime(17) ,1atamxef (27) ,and gentamicin(31). Therapy had no significant effect on haematological or biochemical parameters.There was no increase in the isolation of C1. difficile from stools.CAZ i s a safe and effective drug for use in the treatment of neonates.25 mg/kg dministered b.d. results in adequate serum concentrations w l t h no ccumulation in babies (7 days old.The serum therapeutic ratio for eftazidime against c o m n neonatal pathogens i s superior to that of entamicin and penicill in/ampicill in. A randomized double-blind study, comparing treatment with an a e r o s o l i z e d a n t i v i r a l agent, R i b a v i r i n , 20mg/ml s a l i n e , and a e r o s o l i z e d s a l i n e h a s been conducted i n 26 i n f a n t s (14 Ribavirin. 12 Placebo) with c l i n i c a l l y diagnosed b r o n c h i o l i t i s . Nebulized Ribavirin o r normal s a l i n e a e r o s o l was given f o r 18 hours a day f o r a t l e a s t 3 days. I d e n t i f i c a t i o n of Respiratory S y n c i t i a l v i r u s was made i n n a s a l s e c r e t i o n s from 20 c a s e s (10 Ribavirin, 10 Placebo). Treatment was d e l i v e r e d f o r an average of 68 hours i n t h e Ribavirin group and 65 i n t h e Placebo group. Three times d a i l y c l i n i c a l assessment was made of t h e i n f a n t s . Trends i n 13 o u t of 1 4 c l i n i c a l i n d i c e s recorded favoured a c t i v e treatment. Ribavirin a e r o s o l was a s s o c i a t e d with s i g n i f i c a n t l y f a s t e r improvement and reduction i n cough, c r e p i t a t i o n s , and r e s p i r a t o r y r a t e (P<.05). In t h e 20 i n f a n t s fromwhosenasalsecretions RSV was i d e n t i f i e d most t r e n d s favoured Ribavirin treatment with reduction i n c h e s t recession reaching s t a t i s t i c a l s i g n i f i c a n c e (Pi.05). No d i f f e r e n c e was found i n t h e r a t e of clearance of r e s p i r a t o r y s y n c y t i a l v i r u s . The treatment was well t o l e r a t e d a s judged c l i n i c a l l y and from t h e r e s u l t s of haematological and biochemical s t u d i e s . m e s e o b s e r v a t i o n s suggest nebulized Ribavirin may have a p l a c e i n t h e treatment of some c a s e s of b r o n c h i o l i t i s . kg/day) d u r i n g 6 t o 13 days i n a group of 77 c h i l d r e n w i t h pneumonia, whose ages ranged from 12 months t o 13 y e a r s . C l i n i c a l r e s o l u t i o n was a l i t t l e s u p e r i o r i n t h e group t r e a t e d h r i t h c o -t r i m o x a z o l e , whereas n o r m a l i z a t i o n of l a b o r a t o r y t e s t s and c l e a r n e s s of r o e n t g e n o l o g i c a l images were s i m i l a r i n both groups. Adverse s i d e e f f e c t s were p r e s e n t i n o n l y t h r e e c a s e s ( 2 c o -t r i m o x a z o l e t r e a t e d c a s e s and 1 trimethoprim t r e a t e d c a s e ) , and a l l of them showed a t r a n s i e n t i n c r e a s e of serum ALT and AST d u r i n g 1 t o 4 weeks. One p a t i e n t i n each group r e c e i v e d a m o x i c i l l i n and cefotaxime r e s p e c t i v e l y , because a mild d e t e r i o r a t i o n of t h e c l i n i c a l c o n d i t i o n and of t h e r a d i o l o g i c a l images were n o t i c e d a f t e r 5 days of a n t i b i o t i c therapy. These r e s u l t s show t h a t trimethoprim and co-trimoxaz o l e achieved s i m i l a r t h e r a p e u t i c r e s u l t s i n t h e t r e a t m e n t of pneumonia i n c h i l d r e n .
SULBACTAItT/AM'ICSLLIN I N CHILDREN WITH 1 9 5 BACTEUL PliE~OlTIA
H . S c n o l z , I n s t i t u t e f o r I n f e c t i o u s D i s e a s e s i n C h i l d r e n , Berlin-Buch, GDR Sulbactam i s a b e t a l a c t a m a s e i n h i b i t o r which i n combinat i o n w i t h A m p i c i l l i n expands t h e spectrum o f t h e l a t t e r t o i n c l u d e A m p i c i l l i n r e s i s t a n t g e n s . To document t h e e f f i c a c y a n d s a f e t y o f S u l b a c t a m / A m p i c i l l i n a c l i n i c a l s t u d y was performed i n 25 c h i l d r e n s u f f e r i n g from pneumonia. The dosage o f S u l b a c t a m / A m p i c i l l i n was 5 0 mg Sulbactam/100 mg A m p i c i l l i n p e r kg p e r d a y a h i n i s t e r e d i n t h r e e d i v i d e d doses. C l i n i c a l c u r e was a c h i e v e d i n 22
c h i l d r e n a n d f a i l u r e o f t r e a t m e n t was o b s e r v e d i n 3 c h i ldren. S i d e e f f e c t s o c c u r e d i n 2 p a t i e n t s i n form of t r a ns i e n t exanthema which d i d n o t n e c e s s i t a t e t e r m i n a t i o n o f t r e a t m e n t . S l i g h t and t r a n s i e n t e l e v a t i o n o f transaminas e s was o b s e r v e d i n 4 c h i l d r e n a n d t r a n s i e n t e o s i n o p h il i a o c c u r e d i n 2 p a t i e n t s . The r e s u l t s confirmed t h a t S u l b a c t a m / A m p i c i l l i n i s an e f f e c t i v e a n d w e l l -t o l a r e t e d t r e a t m e n t i n c h i l d r e n w i t h pneumonia. 
i a g n o s i s was confirmed by p o s i t i v e blood o r s t o o l c u l t u r e s a n d / o r by t h e t i t e r of a g g l u t i n i n s . A l l p a t i e n t s had a f a v o u r a b l e c l i n i c a l r e s p o n s e ; f e v e r d i s a p p e a r e d between t h e 3rd and 5 t h day of t h e r a p y (average 5.1 d a y s ) . S u b j e c t i v e improvement a l s o o c c u r r e d i n a s h o r t p e r i o d of time. When t h e t e m p e r a t u r e c u r v e of t h e s e c a s e s was compared t o t h a t from 100 c a s e s t r e a t e d w i t h chloramphenicol ( f e v e r d i s a p p e a r e d on
an average of 7.4 d a y s ) , c o -t r i m o x a z o l e seems t o be a more e f f e c t i v e a n t i m i c r o b i a l a g e n t . R e c e n t l y , e i g h t p a t i e n t s w i t h typhoid f e v e r were given t r i m ethoprim a l o n e (10 mg/kg p e r day) and we o b t a i n e d s i m i l a r good r e s u l t s t h a t w i t h t h e I n f e c t i o u s Diseases Unit. Hospital I n f a n t i l S.Juan de Dios.Barcelona S p a i n . W e r e p o r t o u r r e s u l t s on 110 p a t i e n t s t h a t attended our Hospital during a f o u r years period . The range age was between t h r e e months t o 16 y e a r s .
Short treatment with INH+W during nine months, and a l s o ETB o r S M during t h e f i r s t t h r e e months, i t was given t o the f i r s t group of 61 p a t i e n t s . The same treatment during 12 t o 18 months was done t o a second group of 49 c h i l d r e n .
After treatment suppression, both groups have been c o n t r o l l e d a t l e a s t during one year. At 9 months treatment normal c l i n i c a l examinat i o n was found on a l l p a t i e n t s (110/110), and none showed r e l a p s e . Normal c h e s t X-Ray examination was obtained on 48 over 61 p a t i e n t s of f i r s t group. On 12/61 p a t i e n t s it became normal between 10 and 16 months. On account of b r o n c h i e c t a s i s abnormal images p e r s i s t e d i n one case (1/61).
I n t h e second group normal r a d i o l o g i c a l exam was seen on 17/49 pat i e n t s , when they f i n i s h e d 9 months treatment. And 26/49 p a t i e n t s obt a i n e d it, between 10 and 25 months. Remaining p a t h o l o g i c a l images was due t o b r o n c h i e c t a s i s ( 3 / 4 9 ) , pulmonary s e q u e s t e r ( l / 4 9 ) , fibrocaseous t u b e r c u l o s i s (l/49) and tuberculous granuloma (l/49) .
CONCLUSION:
The above mentioned 9 months treatment i s a b l e t o h e a l t h e d i s e a s e on almost a l l cases. Though afterwards we recomend a follow-up during one y e a r .
